Good point, Creek. However, I am going to assume

Good point, Creek. However, I am going to assume that the numbers are at least close to accurate because it's in the PR. The market is not giving Generex enough credit for the potential to address Type I and Type II diabetes. Besides the full service MSO to meet podiatric and lower extremity needs, there is a captive population for clinical trials. We all remember how much trouble OlGenerex had in designing trials, identifying and enrolling patients, and producing meaningful results. That doesn't even account for the time it took to merely identify and enroll patients. A universe of 25000 individuals in a relatively small geographic area has to expedite every step of the clinical trials for both forms of diabetes.

Speaking of diabetes, who doesn't know a family member, friend, or even someone on this board, that doesn't have to deal with injections, diabetic neuropathies, kidney and heart disease, vision loss, even amputation. Even AG knew the potential of this market, so does Eli Lilly. Most importantly for us, Dr. James Anderson is on our team.